Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:38 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 628 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Non-communicable Disease Clear all

Conditions: COVID-19, SARS CoV 2 Virus, COVID-19 Pneumonia, COVID-19 Respiratory Infection, COVID-19 Acute Respiratory Distress Syndrome
Interventions: A&M Breathalyzer PROTECT Kiosk; Device
Lead sponsor: The Geneva Foundation; Other
Eligibility: 18 Years to 89 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Fort Sam Houston, Texas

Conditions: Chronic UTI, Chronic Urinary Tract Infection
Interventions: No Intervention; Other
Lead sponsor: ProgenaBiome; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2030
U.S. locations: 1
States / cities: Ventura, California

Conditions: Mycoses
Interventions: Voriconazole; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2003
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: HIV Infections
Interventions: Standard (static) Computer Alerts, Enhanced Computer Alerts; Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 1,011 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Erectile Dysfunction, Penile Prosthesis; Complications, Infection or Inflammation
Interventions: Chlorhexidine, Gentamicin, Rifampin; Drug
Lead sponsor: Rush University Medical Center; Other
Eligibility: Male only
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 3
States / cities: Mountain View, California • Chicago, Illinois • Des Plaines, Illinois

Conditions: Hepatitis C Virus (HCV)
Interventions: Glecaprevir/Pibrentasvir Adult Formulation, Glecaprevir + Pibrentasvir Pediatric Formulation; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 3 Years to 17 Years
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 15
States / cities: San Francisco, California • Aurora, Colorado • Hartford, Connecticut + 11 more

Conditions: Cystic Fibrosis, Nontuberculous Mycobacterial Lung Disease, Nontuberculous Mycobacterium Infection, Mycobacterium Infections, Mycobacterium; Pulmonary
Interventions: mycobacteriophage; Biological
Lead sponsor: National Jewish Health; Other
Eligibility: 6 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 18
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 14 more

Conditions: Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Myelodysplastic Syndromes, Chronic Myelogenous Leukemia, Lymphoma,Non-Hodgkin, Lymphoma, Hodgkin, Lymphoma, Follicular, Marginal Zone Lymphoma, Large Cell Lymphoma, Mantle-Cell Lymphoma, Gray Zone Lymphoma, Burkitt Lymphoma, High Risk Undifferentiated Acute Leukemia
Interventions: Bendamustine, Cyclophosphamide; Drug
Lead sponsor: University of Arizona; Other
Eligibility: 4 Years to 30 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2025
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Respiratory Syncytial Virus Infections
Interventions: Not listed
Lead sponsor: MedImmune LLC; Industry
Eligibility: 1 Month to 6 Months
Enrollment: 346 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 59
States / cities: Birmingham, Alabama • Benton, Arkansas • Jonesboro, Arkansas + 50 more

Conditions: Hepatitis C
Interventions: UT-231B; Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 6
States / cities: Gainesville, Florida • New Orleans, Louisiana • Boston, Massachusetts + 3 more

Conditions: Hepatitis C Infection, Thrombocytopenia
Interventions: romiplostim, ribavirin, placebo, PEG-interferon alfa-2a, laboratory biomarker analysis; Biological · Drug · Other
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2018
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Pemphigus Vulgaris, Multiple Sclerosis (MS), Systemic Sclerosis (SSc), Pediatric SLE, Juvenile Idiopathic Arthritis (JIA), Juvenile Dermatomyositis (JDM), Pediatric-Onset Multiple Sclerosis (POMS)
Interventions: Moderna mRNA-1273, BNT162b2, Ad26.COV2.S, Continue IS (MMF or MPA), Continue IS (MTX), Continue IS (B cell depletion therapy), Monovalent [B.1.351] CoV2 preS dTM-AS03, Withhold IS (MMF or MPA), Withhold IS (MTX), Withhold IS (B cell depletion therapy), Moderna mRNA-1273, Bivalent, BNT162b2, Bivalent; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 2 Years and older
Enrollment: 258 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 29
States / cities: Los Angeles, California • New Haven, Connecticut • Atlanta, Georgia + 18 more

Conditions: Uveitis, Uveitis, Posterior, Uveitis, Anterior, Uveitis, Intermediate, Panuveitis
Interventions: 4mg CLS-TA Suprachoriodal Injection, Sham Procedure; Drug
Lead sponsor: Clearside Biomedical, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 40
States / cities: Phoenix, Arizona • Tucson, Arizona • Bakersfield, California + 36 more

Conditions: Bronchiectasis
Interventions: AZLI, Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 274 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 33
States / cities: Florence, Alabama • Flagstaff, Arizona • Peoria, Arizona + 30 more

Conditions: Laparotomy, Dehiscence Wound, Surgical Site Infections, Trauma Abdomen, Emergency General Surgery
Interventions: triclosan-coated barbed suture, triclosan-coated non-barbed suture, Non-coated non-barbed suture; Device
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years to 100 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Trichomonas Vaginitis, Chlamydia Trachomatis, Neisseria Gonorrhoeae Infection
Interventions: Not listed
Lead sponsor: University of Pittsburgh; Other
Eligibility: 15 Years and older · Female only
Enrollment: 305 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: NAFLD, NASH - Nonalcoholic Steatohepatitis, Hiv
Interventions: Not listed
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2031
U.S. locations: 8
States / cities: Birmingham, Alabama • San Diego, California • San Francisco, California + 5 more

Conditions: Infection, Human Immunodeficiency Virus, HIV Infections
Interventions: CAB Oral Tablets, CAB LA, ABC/3TC Oral tablets, RPV Oral Tablets, HAART, RPV; Drug · Other
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 309 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2023
U.S. locations: 15
States / cities: Birmingham, Alabama • Bakersfield, California • Beverly Hills, California + 12 more

Conditions: Uveitis, Anterior
Interventions: EGP-437 1.6 mA-min at 0.4 with EyeGate® II System, EGP-437 4.8 mA-min at 1.2 mA with EyeGate® II System, EGP-437 10.0 mA-min at 2.5 mA with EyeGate® II System, EGP-437 14.0 mA-min at 3.5 mA with EyeGate® II System; Drug
Lead sponsor: Eyegate Pharmaceuticals, Inc.; Industry
Eligibility: 12 Years to 85 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 13
States / cities: Miami, Florida • Atlanta, Georgia • Boston, Massachusetts + 10 more

Conditions: Uveitis
Interventions: fluocinolone acetonide intraocular implant, oral corticosteroid with immunosuppressive agents as needed; Drug
Lead sponsor: JHSPH Center for Clinical Trials; Other
Eligibility: 13 Years and older
Enrollment: 255 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 21
States / cities: La Jolla, California • Los Angeles, California • San Francisco, California + 16 more

Conditions: Anal High Grade Squamous Intraepithelial Lesion, Anal Precancerous Condition, AIN 2/3, HPV Infection, Anal Dysplasia, HPV Disease
Interventions: Artesunate, Placebo; Drug
Lead sponsor: Frantz Viral Therapeutics, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 2
States / cities: Chicago, Illinois • New York, New York

Conditions: Mycoses
Interventions: Voriconazole; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2000
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Chlamydial Infection, Gonococcal Infection
Interventions: Not listed
Lead sponsor: University of California, San Francisco; Other
Eligibility: 16 Years to 75 Years · Female only
Enrollment: 3,500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Syphilis
Interventions: Not listed
Lead sponsor: Chembio Diagnostic Systems, Inc.; Industry
Eligibility: 13 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 3
States / cities: Los Angeles, California • Fort Lauderdale, Florida • Baltimore, Maryland

Search by objective public record fields.

Passive Detection- SARS-CoV-2 (COVID-19) A&M Breathalyzer (PROTECT Kiosk) for Operational Medicine

A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Chronic Urinary Tract Infections (UTI)

Emergency Use of Voriconazole in Patients With Life-Threatening Invasive Fungal Infections

Study of Provider Computer Alerts Designed to Improve Delivery of HIV Care

Irrisept vs Traditional Antibiotic Irrigation for Virgin Penile Prosthesis Placement

A Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Pediatric Subjects With Genotypes 1-6 Chronic Hepatitis C Virus (HCV) Infection

Mycobacteriophage Treatment of Non-tuberculosis Mycobacteria

Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine

Study to Evaluate the Incidence of Hospitalizations and Respiratory Tract Infections in Premature Infants

12 Week Study of Anti-Viral Effect of Oral UT-231B in Non-cirrhotic Hepatitis C Patients who have Failed Interferon-based Therapy.

Romiplostim in Treating Hepatitis C-Infected Patients With Thrombocytopenia

COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders

Suprachoroidal Injection of CLS-TA in Subjects With Macular Edema Associated With Non-infectious Uveitis

Safety and Effectiveness of AZLI (an Inhaled Antibiotic) in Adults With Non-Cystic Fibrosis Bronchiectasis

Barbed Suture vs Non-Barbed Closure for Emergency Exploratory Laparotomy RCT

Non-Invasive Sexually Transmitted Disease Testing in Women Seeking Emergency Contraception or Urine Pregnancy Testing

Nonalcoholic Fatty Liver Disease in HIV Database

A Phase IIb Study to Evaluate a Long-Acting Intramuscular Regimen for Maintenance of Virologic Suppression (Following Induction With an Oral Regimen of GSK1265744 and Abacavir/Lamivudine) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected, Antiretroviral Therapy-Naive Adult Subjects

Safety and Efficacy Study of Iontophoresis and Dexamethasone Phosphate to Treat Anterior Uveitis

Multicenter Uveitis Steroid Treatment (MUST) Trial

Artesunate Suppositories for the Treatment of HIV-negative Patients With Intra-anal HSIL

An Open Label, Non-Comparative, Multicenter, Phase III Trial of the Efficacy, Safety and Toleration of Voriconazole in the Primary or Secondary Treatment of Invasive Fungal Infections

Self-Obtained Vaginal Swabs for Chlamydia and Gonorrhea Testing

Evaluation of the Performance of Chembio's DPP(R) Syphilis Screen & Confirm Rapid Test System